Evidence map›Paper›PMID 39360933›Full record

ReviewFuture oncology (London, England)2024

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.

Ates Kutay Tenekeci, Ahmet Arda Unal, Furkan Ceylan, Mehmet Ali Nahit Sendur

Abstract readReview
In one paragraph

Review in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Lung Adenocarcinoma Developing Pleomorphic Carcinoma WithJTO clinical and research reports · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ates Kutay TenekeciHacettepe University School of Medicine, Ankara, Turkey.ORCID 0009-0007-6224-945X
Ahmet Arda UnalHacettepe University School of Medicine, Ankara, Turkey.ORCID 0000-0001-7156-344X
Furkan CeylanAnkara Bilkent City Hospital, Department of Medical Oncology, Ankara, Turkey.
Mehmet Ali Nahit SendurAnkara Yildirim Beyazit University Faculty of Medicine and Ankara Bilkent City Hospital, Department of Medical Oncology, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)Antineoplastic AgentsBiomarkers, TumorDrug Resistance, NeoplasmHumansMolecular Targeted TherapyNeoplasm StagingPiperazinesPyridinesPyrimidinesAntineoplastic AgentsBiomarkers, TumorKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasibadagrasibKRAS G12C inhibitorsnon-small cell lung cancer (NSCLC)precision oncologyresistance mechanismssotorasibtargeted treatments

Identifiers

PMID39360933
PMCPMC11572139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.